NCT01152801View on ClinicalTrials.gov

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Everolimus (RAD001)

Trial Locations (7)

100028

Novartis Investigative Site, Beijing

100036

Novartis Investigative Site, Beijing

200127

Novartis Investigative Site, Shanghai

200433

Novartis Investigative Site, Shanghai

210002

Novartis Investigative Site, Nanjing

430030

Novartis Investigative Site, Wuhan

510060

Novartis Investigative Site, Guangzhou

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY